SC
DXCM icon

Scholtz & Company’s DexCom DXCM Stock Holding History

Scholtz & Company’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.21M Buy
77,334
+8,686
+13% +$579K 2.6% 13
2026
Q1 		$4.31M Buy
68,648
+309
+0.5% +$21.5K 2.21% 18
2025
Q4 		$4.54M Buy
68,339
+36,392
+114% +$2.35M 1.97% 18
2025
Q3 		$2.15M Buy
31,947
+25,261
+378% +$2M 0.94% 36
2025
Q2 		$584K Buy
6,686
+90
+1% +$7.05K 0.26% 40
2025
Q1 		$450K Buy
+6,596
New +$538K 0.22% 40
2024
Q4 		– Sell
-25,527
Closed -$1.71M – 50
2024
Q3 		$1.71M Sell
25,527
-1,330
-5% -$109K 0.81% 33
2024
Q2 		$3.05M Buy
26,857
+1,059
+4% +$134K 1.3% 27
2024
Q1 		$3.58M Buy
25,798
+3,259
+14% +$410K 1.58% 25
2023
Q4 		$2.8M Buy
+22,539
New +$2.3M 1.38% 25

Other funds holding DXCM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Scholtz & Company's DXCM Position: Q2 2026 in Review

Scholtz & Company increased its DexCom (DXCM) stake by 13% in Q2 2026, buying an estimated $579K and bringing the position to 77,334 shares worth $5.21M. The position accounts for 2.6% of the portfolio, ranked #13.

Scholtz & Company first reported a position in DXCM in Q4 2023 and has held it in 10 quarters since. 973 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • Scholtz & Company held 77,334 shares of DexCom worth $5.21M as of Q2 2026.
  • Scholtz & Company bought 8,686 DexCom shares in Q2 2026, an estimated $579K.
  • DexCom made up 2.6% of Scholtz & Company's portfolio in Q2 2026, its #13 holding.
  • Scholtz & Company first reported a position in DexCom in Q4 2023 and has held it in 10 quarters since.
  • 973 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Scholtz & Company's 13F filing for Q2 2026, filed 11 Aug 2026.